JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266459

Human HNRNPAB knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

HNRNPAB KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 5 bp deletion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

ABBP-1, APOBEC1-binding protein 1, Apolipoprotein B mRNA editing enzyme catalytic polypeptide 1- protein 1, FLJ40338, HNRNPAB, Heterogeneous nuclear ribonucleoprotein A/B, ROAA_HUMAN, hnRNP A/B, hnRNP type A/B protein

2 Images
Western blot - Human HNRNPAB knockout HEK-293T cell line (AB266459)
  • WB

Lab

Western blot - Human HNRNPAB knockout HEK-293T cell line (AB266459)

Lanes 1-4 : Merged signal (red and green). Green - ab199724 observed at 48 kDa. Red - loading control ab8245 observed at 36 kDa.

ab199724 Anti-HNRPab antibody [EPR16944] was shown to specifically react with HNRPab in wild-type HEK293T cells. Loss of signal was observed when knockout cell line ab266459 (knockout cell lysate ab257467) was used. Wild-type and HNRPab knockout samples were subjected to SDS-PAGE. ab199724 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2. 5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-HNRPAB antibody [EPR16944] (<a href='/en-us/products/primary-antibodies/hnrpab-antibody-epr16944-ab199724'>ab199724</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK293T cell lysate at 20 µg

Lane 2:

HNRNPAB knockout HEK293T cell lysate at 20 µg

Lane 2:

Western blot - Human HNRNPAB knockout HEK-293T cell line (ab266459)

Lane 3:

K-562 cell lysate at 20 µg

Lane 4:

Jurkat cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 36 kDa

Observed band size: 48 kDa

false

Sanger Sequencing - Human HNRNPAB knockout HEK-293T cell line (AB266459)
  • Sanger seq

Unknown

Sanger Sequencing - Human HNRNPAB knockout HEK-293T cell line (AB266459)

Homozygous : 5 bp deletion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 5 bp deletion in exon 2

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266459-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266459 Human HNRNPAB knockout HEK-293T cell line", "number":"AB266459-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266459-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266459-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266459 Human HNRNPAB knockout HEK-293T cell line", "number":"AB266459-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266459-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266459-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266459 Human HNRNPAB knockout HEK-293T cell line", "number":"AB266459-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266459-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266459 Human HNRNPAB knockout HEK-293T cell line", "number":"AB266459-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
HNRNPAB
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Heterogeneous nuclear ribonucleoprotein A/B often called HNRPAB functions as a part of the ribonucleoprotein complex. This protein interacts with pre-mRNA in the nucleus and influences its processing. HNRPAB has a molecular mass of about 37 kilodaltons. Scientists find it highly expressed in various tissues including the brain and testis indicating its significant role in these areas. The protein contains RNA-binding domains and plays a part in the regulation of alternative splicing.
Biological function summary

HNRPAB influences the splicing and transport of pre-mRNA impacting the maturation process of mRNA. It collaborates with other hnRNPs and splicing factors to modulate gene expression. The protein sometimes forms part of larger complexes that are essential for RNA processing. This complex helps to stabilize RNA molecules assisting in their proper transport and translation in the cytoplasm.

Pathways

HNRPAB is involved in the regulation of RNA metabolism and processing pathways. It forms a network with other proteins like hnRNP F and hnRNP H impacting gene expression by influencing mRNA stability and availability. In conjunction with these proteins HNRPAB plays a role in the signal transduction pathways affecting cellular responses and adaptations.

HNRPAB has connections to cancer and neurodegenerative disorders. Its dysregulation can lead to abnormal splicing patterns contributing to oncogenesis. In cancer associations with proteins like c-Myc indicate a role in tumorigenesis. In neurodegenerative diseases altered HNRPAB activity could impact neuronal survival contributing to the progression of disorders like Alzheimer's disease. The protein's interaction with tau suggests a potential link to tauopathies which are related to abnormal protein aggregations within neurons.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com